Application No.: 09/996357 Docket No.: PPI-105

Amendments to the Specification

Please replace the paragraph at page 14, lines 13-26 with the following amended paragraph:

In a preferred embodiment, the "P" component in the compounds of the invention is designed based upon the amino acid sequence of an "A β aggregation core domain" (ACD). As used herein, the term "A β aggregation core domain" refers to a subregion of a natural β -amyloid peptide that is sufficient to modulate aggregation of natural β -APs when this subregion, in its L-amino acid form, is appropriately modified (e.g., modified at the amino-terminus), as described in detail in U.S. patent application Serial No. 08/548,998, now abandoned, and U.S. patent application Serial No. 08/616,081, now abandoned, the entire contents of each of which are expressly incorporated herein by reference. Preferably, the "P" component in the compounds of the invention is or is modeled after a subregion of natural β -AP that is less than 15 amino acids in length and more preferably is between 3-10 amino acids in length. In various embodiments, the "P" component in the compounds of the invention is, or is modeled after, a subregion of β -AP that is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more amino acids in length.

Please replace the paragraph at page 6, lines 6-9 with the following paragraph:

Figures 2A-L depicts an immunohistochemistry analysis of coronal brain sections from 20-22 week mice transgenic for both the Swedish mutation of amyloid precursor protein and presentiin of mouse IgG1 fused to various segments of β -amyloid, medium from nontransfected COS cells, or anti- β -amyloid polyclonal antibody.

Please replace the paragraph at page 6, lines 25-27 with the following paragraph:

Figures 8A-B is a are graphs demonstrating that Fc receptor-mediated fibril uptake by cells occurs in the presence of either the A β (16-30)-Fc fusion protein or the α - β -amyloid antibody.